trial · primary record
Intralesional FLD-103
Nodular Basal Cell Carcinoma
| Phase | Phase 1 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2026-10-26 |
| Primary endpoint | Frequency, severity and relationship of Treatment Emergent Adverse events (TEAEs) |
| Registry ID | NCT07670858 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:28.453Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07670858
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.